Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171446101> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2171446101 endingPage "1008" @default.
- W2171446101 startingPage "1003" @default.
- W2171446101 abstract "The long intracellular half-life of gemcitabine’s active metabolite, difluorodeoxycytidine triphosphate (dFdCTP), suggested that small increases in peak intracellular dFdCTP levels would have a profound effect on its intracellular area under the curve (AUC). Previous studies had shown that a dose rate of 10 mg/m2/min that achieved plasma gemcitabine concentrations of 15-20 μmol/1 maximized the intracellular rate of accumulation of dFdCTP. This phase I study was therefore designed to evaluate the clinical feasibility of this pharmacologically-based strategy; assessing the toxic effects and anticancer activity of high weekly doses of gemcitabine administered at a fixed dose rate of 10 mg/m2/min. Thirty one patients with solid tumor malignancies received 103 courses of gemcitabine. Twenty nine patients had received prior treatment. Weekly doses were escalated from 1200 mg/m2 administered intravenously over 120 minutes to 2800 mg/m2 over 280 minutes for three weeks every four weeks. The first-course MTD was 2250 mg/m2. The dose-limiting toxicity was myelosuppression with thrombocytopenia and granulocytopenia quantitatively more important than anemia. However, cumulative myelosuppression was documented suggesting that a lower MTD of 1800 mg/m2 was more appropriate with a recommended phase II starting dose of 1500 mg/m2. There was no neurologic toxicity. Nonhematologic toxicity was minimal and included fatigue, nausea, and skin rash, but was not dose dependent. Three objective responses were documented. Escalated doses of gemcitabine designed to maximize intracellular dFdCTP levels can be safely administered using a fixed dose rate. The encouraging anticancer effects documented in patients with refractory malignancies suggests that short gemcitabine infusions based on well-established cellular pharmacologic principles may improve the therapeutic index of this agent. Comparison with standard 30-minute bolus dosing will be evaluated in subsequent randomized phase II trials." @default.
- W2171446101 created "2016-06-24" @default.
- W2171446101 creator A5034770005 @default.
- W2171446101 creator A5036290225 @default.
- W2171446101 creator A5046211728 @default.
- W2171446101 creator A5073107187 @default.
- W2171446101 creator A5087376683 @default.
- W2171446101 date "1998-09-01" @default.
- W2171446101 modified "2023-10-18" @default.
- W2171446101 title "Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors" @default.
- W2171446101 cites W1788009048 @default.
- W2171446101 cites W1857358013 @default.
- W2171446101 cites W1858072261 @default.
- W2171446101 cites W1890647543 @default.
- W2171446101 cites W1924785021 @default.
- W2171446101 cites W1931508686 @default.
- W2171446101 cites W2083470546 @default.
- W2171446101 cites W2089062211 @default.
- W2171446101 cites W2130164889 @default.
- W2171446101 cites W2135352785 @default.
- W2171446101 cites W2154737435 @default.
- W2171446101 cites W2167805334 @default.
- W2171446101 cites W2265767948 @default.
- W2171446101 cites W2270490184 @default.
- W2171446101 cites W2290505379 @default.
- W2171446101 doi "https://doi.org/10.1023/a:1008487932384" @default.
- W2171446101 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9818075" @default.
- W2171446101 hasPublicationYear "1998" @default.
- W2171446101 type Work @default.
- W2171446101 sameAs 2171446101 @default.
- W2171446101 citedByCount "89" @default.
- W2171446101 countsByYear W21714461012012 @default.
- W2171446101 countsByYear W21714461012014 @default.
- W2171446101 countsByYear W21714461012015 @default.
- W2171446101 countsByYear W21714461012016 @default.
- W2171446101 countsByYear W21714461012017 @default.
- W2171446101 countsByYear W21714461012020 @default.
- W2171446101 crossrefType "journal-article" @default.
- W2171446101 hasAuthorship W2171446101A5034770005 @default.
- W2171446101 hasAuthorship W2171446101A5036290225 @default.
- W2171446101 hasAuthorship W2171446101A5046211728 @default.
- W2171446101 hasAuthorship W2171446101A5073107187 @default.
- W2171446101 hasAuthorship W2171446101A5087376683 @default.
- W2171446101 hasBestOaLocation W21714461011 @default.
- W2171446101 hasConcept C112705442 @default.
- W2171446101 hasConcept C126322002 @default.
- W2171446101 hasConcept C2776694085 @default.
- W2171446101 hasConcept C2777288759 @default.
- W2171446101 hasConcept C2778397455 @default.
- W2171446101 hasConcept C2778570526 @default.
- W2171446101 hasConcept C2780258809 @default.
- W2171446101 hasConcept C2780580376 @default.
- W2171446101 hasConcept C29730261 @default.
- W2171446101 hasConcept C71924100 @default.
- W2171446101 hasConcept C90924648 @default.
- W2171446101 hasConcept C98274493 @default.
- W2171446101 hasConceptScore W2171446101C112705442 @default.
- W2171446101 hasConceptScore W2171446101C126322002 @default.
- W2171446101 hasConceptScore W2171446101C2776694085 @default.
- W2171446101 hasConceptScore W2171446101C2777288759 @default.
- W2171446101 hasConceptScore W2171446101C2778397455 @default.
- W2171446101 hasConceptScore W2171446101C2778570526 @default.
- W2171446101 hasConceptScore W2171446101C2780258809 @default.
- W2171446101 hasConceptScore W2171446101C2780580376 @default.
- W2171446101 hasConceptScore W2171446101C29730261 @default.
- W2171446101 hasConceptScore W2171446101C71924100 @default.
- W2171446101 hasConceptScore W2171446101C90924648 @default.
- W2171446101 hasConceptScore W2171446101C98274493 @default.
- W2171446101 hasIssue "9" @default.
- W2171446101 hasLocation W21714461011 @default.
- W2171446101 hasLocation W21714461012 @default.
- W2171446101 hasOpenAccess W2171446101 @default.
- W2171446101 hasPrimaryLocation W21714461011 @default.
- W2171446101 hasRelatedWork W1552629127 @default.
- W2171446101 hasRelatedWork W1898871412 @default.
- W2171446101 hasRelatedWork W2004325424 @default.
- W2171446101 hasRelatedWork W2004787353 @default.
- W2171446101 hasRelatedWork W2044828056 @default.
- W2171446101 hasRelatedWork W2151634703 @default.
- W2171446101 hasRelatedWork W2183535825 @default.
- W2171446101 hasRelatedWork W2774225352 @default.
- W2171446101 hasRelatedWork W2793520024 @default.
- W2171446101 hasRelatedWork W3021369409 @default.
- W2171446101 hasVolume "9" @default.
- W2171446101 isParatext "false" @default.
- W2171446101 isRetracted "false" @default.
- W2171446101 magId "2171446101" @default.
- W2171446101 workType "article" @default.